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Prions are unconventional infectious agents com-
posed exclusively of misfolded prion protein (PrPSc),
which transmits the disease by propagating its ab-
normal conformation to the cellular prion protein
(PrPC). A key characteristic of prions is their species
barrier, by which prions from one species can only
infect a limited number of other species. Here, we re-
port the generation of infectious prions by interspe-
cies transmission of PrPSc misfolding by in vitro
PMCA amplification. Hamster PrPC misfolded by
mixing with mouse PrPSc generated unique prions
that were infectious to wild-type hamsters, and sim-
ilar results were obtained in the opposite direction.
Successive rounds of PMCA amplification result in
adaptation of the in vitro-produced prions, in a pro-
cess reminiscent of strain stabilization observed
upon serial passage in vivo. Our results indicate
that PMCA is a valuable tool for the investigation of
cross-species transmission and suggest that spe-
cies barrier and strain generation are determined by
the propagation of PrP misfolding.
INTRODUCTION
Prion diseases also known as transmissible spongiform enceph-
alopathies (TSEs) are infectious neurodegenerative diseases af-
fecting the brain of humans and several species of mammals
(Collinge, 2001). Creutzfeldt-Jakob disease (CJD) is the most
common TSE in humans, and scrapie in sheep, bovine spongi-
form encephalopathy (BSE) in cattle, and chronic wasting dis-
ease (CWD) in cervids are the most prevalent prion diseases in
animals. Unlike conventional infectious microorganisms, the
TSE agent appears to be devoid of genetic material and instead
composed exclusively by a misfolded form of the prion protein
(PrPSc) (Prusiner, 1998). PrPSc has the unprecedented ability toreplicate in the body by inducing the misfolding of the cellular
form of the prion protein (PrPC).
One of the characteristics of the agent responsible for prion
diseases is its ability to infect some species and not others (Hill
and Collinge, 2004; Moore et al., 2005). This phenomenon is
known as species barrier. Even between close species, the spe-
cies barrier is manifested as an incomplete attack rate and a pro-
longation of the time it takes for animals to develop the clinical
disease when injected with another species’ infectious material
(Hill and Collinge, 2004). Primary interspecies transmission is
usually not very efficient, and it takes a long time for the prion
replication process to reach the point at which full-blown clinical
disease appears. After sequential passages, the PrPSc in the new
host adapts, resulting in a shortage of the incubation period and
stabilization of the new strain (Hill and Collinge, 2004).
Compelling evidence indicates that the species barrier is
largely controlled by the sequence of PrP (Moore et al., 2005).
Unfortunately, we cannot predict the degree of a species barrier
simply by comparing the prion proteins from two species. The
barrier has to be measured by experimental studies in animals.
These studies are long and costly, and in the case of the human
species barrier, the studies have to be done with experimental
models, the validity of which is not absolutely guarantied. Evalu-
ation of the species barrier is of tremendous medical importance
for risk assessment and to implement regulatory measures to
avoid spreading of diseases (Moore et al., 2005). At this time,
the epidemiological evidence suggests that among animal
TSEs only cattle BSE has been transmitted to humans, generat-
ing a variant form of CJD (vCJD) (Will et al., 1996). It is unlikely
that sheep scrapie is a concern for humans, because the disease
has been described for centuries and no increased prevalence of
human prion diseases has been found in scrapie-endemic areas
(Caramelli et al., 2006; Hunter, 1998). However, the appearance
of ‘‘atypical’’ strains of scrapie, as well as the known transmis-
sion of BSE to sheep, has generated new concerns of human
infections with sheep-derived material (Buschmann and
Groschup, 2005; Hunter, 2003). Similarly, the possibility that
some of the newly identified animal prion diseases, such as
CWD, could be transmitted to humans cannot be ruled out at
the present time (Williams, 2005; Xie et al., 2005).Cell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc. 757
Recently, we reported the generation of infectious prions
in vitro by amplification of PrPSc misfolding in the test tube (Cas-
tilla et al., 2005). For these experiments, we used a technology
termed PMCA (protein misfolding cyclic amplification) that
mimics in vitro some of the fundamental steps involved in PrPSc
replication in vivo at an accelerated rate (Saborio et al., 2001).
During PMCA, small quantities of PrPSc are mixed with excess
of PrPC, and through a cyclical process involving incubation
and sonication, prion propagation occurs in an autocatalytic
way. With this procedure, prions can replicate indefinitely in
the test tube and, after successive rounds of dilutions followed
by PMCA amplification, PrPSc used to begin the reaction can
be eliminated, and only in vitro-generated misfolded protein
remains in the sample (Castilla et al., 2005). Inoculation of
PMCA-generated prions into wild-type animals resulted in a dis-
ease with the same clinical, neuropathological, and biochemical
features as the disease produced by brain-derived infectious
material (Castilla et al., 2005). The conclusion drawn from these
findings is that all of the information required to propagate the
infectious properties is enciphered in the structure of PrPSc.
This is further supported by recent studies from Supattapone
and coworkers in which infectious prions were generated
in vitro by PMCA with purified PrPC and PrPSc with the sole ad-
dition of synthetic polyanions (Deleault et al., 2007).
The goal of this study was to attempt crossing the species
barrier in vitro to generate unique infectious prions in a cell-
free system. For these studies, we used mice and hamsters,
two experimental rodent systems widely employed in TSE stud-
ies and for which several prion strains are available (Bruce, 2003;
Kimberlin and Walker, 1988). The PrP sequence shows nine dif-
ferences between these two animal species (Figure 1A). Infectiv-
ity studies have shown that there is a large barrier for prion trans-
mission between these species (Kimberlin et al., 1989; Kimberlin
and Walker, 1988; Race et al., 2002). Our findings show that in-
cubation of PrPC from one of the species with PrPSc from the
other resulted in new PrPSc that was infectious to wild-type ani-
mals. Interestingly, a detailed examination of the infectious, neu-
ropathological, and biochemical features of the disease that was
produced revealed characteristics that were different from other
known prion strains. These results indicate that the prions gener-
ated in vitro by crossing of the mouse-hamster barrier represent
new strains. Strikingly, studies of the infectious characteristics of
these newly generated prions after different rounds of PMCA
showed that the procedure not only enabled crossing of the spe-
cies barrier but also resulted in stabilization of the new strain
in vitro by successive rounds of amplification. Our findings
show that prions can be propagated in vitro across the species
barrier, leading to the generation and adaptation of unique prion
strains.
RESULTS
Crossing the Mouse-Hamster Species Barrier
to Generate New Hamster Prions
To assess whether prions can be generated in vitro across the
species barrier, we used hamsters and mice, two widely studied
rodent experimental models of TSEs (Bruce, 2003; Kimberlin and
Walker, 1988; Morales et al., 2007). A PMCA experiment done758 Cell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc.with our standard conditions for amplification of mouse RML
prions showed no detectable formation of PrPSc when hamster
PrPC was used as a substrate (Figure 1A). Conversely, a robust
PrPSc generation was observed with mouse PrPC substrate.
For this experiment, we mixed a 1000-fold dilution of RML PrPSc
Figure 1. In Vitro Conversion of Hamster PrPC Induced by Mouse
RML PrPSc
(A) RML brain homogenate was diluted 1000-fold into either mouse or hamster
normal brain homogenate and subjected to 96 PMCA cycles. The blot shows
the results with and without PMCA in each species. At the right side, we show
a scheme of PrP indicating the position in which there are amino acid differ-
ences between mice and hamsters.
(B) To attempt forcing conversion, we incubated larger quantities (dilutions
1:50 through 1:800) of RML PrPSc with mouse (central panel) or hamster (right
panel) PrPC. All samples (except for the control samples in the left panel la-
beled ‘‘nonamplified’’) were subjected to 96 PMCA cycles, and PrPSc signal
was detected after PK digestion by western blot with the 6H4 antibody.
(C) The same samples as those in the right panel of (B) were developedwith the
3F4 antibody.
(D) The newly generated RML-Ha PrPSc was serially passed in hamster brain
homogenate by a series of 1:10 dilution followed by 48 PMCA cycles. ‘‘R’’ in-
dicates the number of rounds of PMCA; i.e., R5 represent the samples after
five serial rounds of PMCA.
(E) For the assessment of spontaneous generation of PrPSc by PMCA, samples
from brain of ten different hamsters were subjected to the same process of se-
rial PMCA as in (D). PrPSc formation was analyzed by western blot after PK
treatment in each PMCA round. The figure shows the results obtained after
20 rounds of PMCA. In the experiments shown in this figure, all samples
were treated with PK, except when indicated.
into 10% brain homogenates of healthy hamsters and mice, re-
spectively. We reasoned that if in vivo it takes longer for prions to
replicate across species barriers, then in PMCA we should also
encounter more difficulties to convert PrPC when using PrPSc
from a different species. To attempt forcing the in vitro conver-
sion, we added a higher proportion of PrPSc-containing mouse
brain homogenate into the hamster substrate. A range of dilu-
tions from 50- to 800-fold were tested, but the problem with
these experiments is that the large concentration of RML PrPSc
used as inoculum makes it difficult to estimate convincingly
whether new PrPSc generation was obtained (Figure 1B). Fortu-
nately, the 3F4 monoclonal antibody can recognize hamster but
not mouse PrP (Lund et al., 2007). Using this antibody for west-
ern blot, we could clearly observe that protease-resistant ham-
ster PrPSc was being produced when the reaction was done
with low dilutions (from 1:50 to 1:200) of mouse RML PrPSc
(Figure 1C). When the amplification was attempted with 800-
fold diluted PrPSc-containing mouse brain homogenate, only
a very faint signal was observed, confirming the results obtained
in Figure 1A and the idea that the combination of PrPC and PrPSc
from different species impairs PMCA efficiency.
Newly generated hamster PrPSc starting from RML prions was
propagated many times in vitro by serial PMCA in order to re-
move by dilution the initial amount of mouse scrapie brain mate-
rial added to begin prion replication (Figure 1D). As described
before, using this procedure, we can completely remove all mol-
ecules of brain-derived PrPSc from the sample (Castilla et al.,
2005). Hamster PrPSc of RML origin efficiently propagates
in vitro at the expense of hamster PrPC. Interestingly, in the first
PMCA round, the glycoform distribution pattern of the in vitro-
generated hamster PrPSc was comparable to the RML profile
showing the three glycoform bands (Figure 1D). After further
PMCA rounds, this pattern changed to become undistinguish-
able from PrPSc associated to the typical hamster strains, such
as 263K (Figure 1D) or Hyper (HY), in which the diglycosylated
band is highly predominant. This result suggests that the charac-
teristics of the newly generated PrPSc are being adapted to the
new species during successive PMCA cycling, reminiscent of
the adaptation process occurring in vivo upon serial passage
of the infectious material. After 20 serial rounds of PMCA, repre-
senting a dilution equivalent to 1022 with respect to the brain
(since the first round contains a 100-fold dilution of the material),
our estimation is that no molecules of mouse brain PrPSc should
be present in the sample. This in vitro-generated material was
termed RML-Ha PrPSc to emphasize the RML origin of this
new hamster misfolded prion protein. To make sure that newly
formed PrPSc was indeed coming from conversion of hamster
PrPC induced by mouse PrPSc and not just spontaneous ‘‘de
novo’’ formation of PrPSc in hamsters (Deleault et al., 2007), we
did a large experiment to analyze in detail the possibility of spon-
taneous generation of PrPSc and infectivity under our experimen-
tal conditions. Samples of healthy brain homogenate from ten
different hamsters were subjected to serial rounds of PMCA am-
plification in the absence of PrPSc seed. After up to 20 serial
rounds of PMCA, we did not observe de novo formation of PrPSc
in any of the samples (Figure 1E).
Inoculation of wild-type hamsters with RML-Ha PrPSc (pro-
duced after a 1022 dilution of RML scrapie brain homogenate)produced disease in 100% of the animals by both intracerebral
(i.c.) and intraperitoneal (i.p.) routes (Figure 2). The disease ex-
hibits the clinical characteristics typical of hamster scrapie, in-
cluding hyperactivity, motor impairment, head wobbling, muscle
weakness, and weight loss. The incubation time in the first pas-
sage was 165 ± 6 days by i.c. inoculation (Figures 2A and 2C).
This is longer than the incubation time obtained with hamster
scrapie strains, such as 263K and HY, in which a similar quantity
of PrPSc produces disease at around 100 days by this route (Fig-
ures 2A and 2C). However, in agreement with our previously re-
ported data (Castilla et al., 2005), when hamster 263K prions
were replicated in vitro by PMCA, the newly generated PrPSc pro-
duceddiseasewith a delay similar to that observedwith theRML-
Ha material (Figures 2A and 2C). The delay in our previous study
was eliminated upon a second passage in vivo, in which the
new infectious material was stabilized to acquire properties un-
distinguishable from in vivo-derived 263K (Figures 2B and 2C).
Interestingly, in the HY hamster prion strain, PMCA-generated
material did not show any statistically significant difference
compared to in vivo-produced prions (Figures 2A and 2C). These
results suggest that in vitro replication of prions by PMCA main-
tains thestrain characteristics, at least in respect to the incubation
periods. To assess the stability of RML-Ha and estimate the sta-
bilized incubation period, we performed a second passage. As
shown inFigure2B, the incubation timeofRML-Haprionswasde-
creased to around 90 days, which is very similar to that obtained
with 263KandHYbut different from theDrowsy (DY) strain. These
results suggest that RML-Ha prions behave similarly to the 263K
strain; both in vitro-generated prions show a delay in the first pas-
sage that gets corrected upon a second in vivo passage. This fea-
ture is notdisplayedbyother hamster prion strains, suchasHY, or
other species of prions (see below for the results in mice), where
PMCA-generated prions exhibited the same incubation period in
the first passage as in vivo-produced infectious material. As ex-
pected, hamsters inoculatedwithRMLprionsdidnotdevelopdis-
ease during the time of the experiment (>400 days). Animals inoc-
ulated with hamster brain homogenate subjected to 20 rounds of
PMCA in the absence of PrPSc (control for the de novo generation
of PrPSc) did not develop disease more than 400 days after inoc-
ulation (Figures 2A and 2C). Intraperitoneal inoculations of the in-
fectious material showed a clear difference between the three
prion strains used as reference, with 263K being the fastest and
DY not producing disease by this route (Figure 2D). The incuba-
tion period produced by i.p. inoculation of RML-Ha prions was
longer than that of the 263K and HY strains, with an average of
254 days in the first passage. This is also longer than 263K prions
amplified in vitro by PMCA, which produced disease after 199
days postinoculation in the first passage (Figures 2D and 2F). A
second in vivo passage again stabilized PMCA-generated 263K
prions to produce disease at a time indistinguishable from that
of brain-derived 263K infectious material. The second passage
of RML-Ha prions showed that the stabilized incubation period
for the i.p. routewas on average around 140 days, which is signif-
icantly higher than 263K or 263K-PMCAmaterial but shorter than
HY prions (Figures 2E and 2F). The differences remained stable in
a third passage (data not shown). These results indicate that in
some aspects, RML-Ha prions are similar to the agent in the
263K strain but in other features are intermediate between 263KCell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc. 759
Figure 2. Infectivity of Newly Generated RML-Ha PrPSc after Crossing the Species Barrier
RML-Ha PrPSc samples amplified by 20 serial PMCA rounds were inoculated i.c. or i.p. into six wild-type hamsters. For controls, we inoculated similar quantities
of PrPSc fromRML or three distinct hamster strains (263K, Hyper, andDrowsy). We also show the data obtained by inoculation of in vitro-generated prions through
20 serial rounds of PMCA by incubation of 263K (263K-PMCA) or Hyper (HY-PMCA) PrPSc with healthy hamster brain homogenate and RML replicated at ex-
penses of mouse PrPC (RML-PMCA). The figure also show the results obtained by inoculation of the material produced after 20 rounds of PMCA with unseeded
normal hamster brain homogenate (PMCA-No PrPSc). (A) and (D) show the survival curves obtained after i.c. and i.p. inoculation, respectively, of the in vitro-gen-
erated RML-Ha after 20 rounds of PMCA. (B) and (E) show the survival curves of the second passage (i.e., animals were inoculated withmaterial obtained from the
brain of sick animals in the experiments depicted in [A] and [D]) after i.c and i.p inoculation, respectively. (C) and (F) show the average incubation periods of the
experiments done by i.c. and i.p. inoculation of various samples. The values correspond to the average ± standard error. The data was analyzed by ANOVA and
the Dunnett multiple comparison post-test. Each set of data was compared to the results obtained with the RML-Ha strain, and significant differences are high-
lighted with asterisks (* = p < 0.05, ** = p < 0.01, and *** = p < 0.001). ND, not done.and HY prions, providing a first indication that the material ob-
tained by crossing of the mouse-hamster species barrier repre-
sents a unique hamster prion strain.
To further assess the characteristics of the disease produced
by in vitro-generated RML-Ha prions, we studied in detail the
neuropathological and biochemical features of the brain dam-
age. Histopathological studies showed that animals inoculated
with RML-Ha prions exhibit the typical brain lesions of scrapie,
including spongiform degeneration, astroglyosis, and PrPSc de-
position (Figures 3A–3C). Quantitative studies of the vacuolation
profile in different brain areas showed that RML-Ha-infected
hamsters showed the largest extent of spongiosis in medulla
and cerebellum and less damage in hippocampus, cortex, and
colliculum (Figure 3D). This pattern of brain damage was similar
to that observed in 263K-inoculated animals and statistically
different from that obtained in hamsters injected with HY and
DY (Figure 3D). However, the extent of both astroglyosis
(Figure 3B) and PrPSc accumulation (Figure 3C) in the medulla
of RML-Ha-infected animals was lower than that in 263K-sick
animals and similar to that observed in HY-injected hamsters760 Cell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc.(Figures 3B and 3C). These data suggest again that the RML-
Ha prions are a unique strain with properties intermediate be-
tween the previously known 263K and HY hamster strains.
Comparative studies of the biochemical characteristics of
PrPSc obtained from the brain of sick animals after inoculation
with RML-Ha, 263K, HY, and DY were done by analysis of the
electrophoretical pattern of the protein, its susceptibility to pro-
teolytic degradation, and its resistance to denaturation. For
comparison of the protease resistance profile, similar quantities
of PrPSc from the new RML-Ha prions and PrPSc obtained from
the brain of sick hamsters inoculated with the prion strains
263K, HY, and DY were treated for 60 min with various concen-
trations of proteinase K (PK) (Figure 4A). RML-Ha PrPSc was
highly resistant to large PK concentrations. The misfolded pro-
tein associated to the newly generated strain was more resistant
than HY or DY and similarly (but still significantly more) suscep-
tible to PK digestion than 263K PrPSc (Figure 4A). The PK con-
centration in which 50% of the protein was degraded (PK50)
was highest for PrPSc associated to RML-Ha, followed by
263K, HY, DY, and RML (Table S1 available online).
Figure 3. Histopathological Features of the
Disease Induced by Inoculation of Hamsters
with PMCA-Generated RML-Ha PrPSc
Brain from sick animals in which disease was pro-
duced by inoculation with the in vitro-generated
RML-Ha PrPSc (first passage) or the known ham-
ster strains 263K, Hyper, and Drowsy were ana-
lyzed by histological studies. As a control, we
used the brain of a hamster inoculated with PBS
and sacrificedwithout disease at 350 days after in-
oculation.
(A) Spongiform degeneration was evaluated after
hematoxilin-eosin staining of medulla and occipi-
tal cortex sections and visualized by microscopy
at a 403 magnification.
(B) Reactive astroglyosis was evaluated by histo-
logical staining with glial fibrillary acidic protein an-
tibody.
(C) PrP accumulation in these animals was evalu-
ated by staining of the tissue with the 3F4 anti-
PrP monoclonal antibody.
(D) The vacuolation profile in each brain area was
estimated with a semiquantitative scale, as de-
scribed in the Experimental Procedures. The brain
areas used were the following: occipital cortex,
cerebellum (mostly white matter), medulla (spinal
5 nucleus, interpolar part), inferior colliculum, and
hippocampus (CA1 and CA2 regions). We also in-
cluded in the analysis brain sections from animals
inoculated with the other hamster prion strains.
The values represent the average ± standard error
of the extent of vacuolation from the five animals
analyzed in each set. Statistical analysis by
two-way ANOVA with brain regions and prion ori-
gin as the variables indicated that differences were highly significant (p < 0.001). To assess the significance of the differences between each known prion strain
and RML-Ha, we used the Dunnett multiple comparison post-test, and the p values for each combination are shown.Another characteristic we studiedwas the electrophoretic mo-
bility and glycosylation pattern of PrPSc associated to distinct
strains. The predominant glycoform for the hamster strains (in-
cluding the newly generated RML-Ha) is the diglycosylated
band,whereasmouseRMLPrPSc showsamoreevendistribution
of the three bandswith themain one being themonoglycosylated
form. To assess the size of the protein after PK cleavage, we per-
formed endoglycosidase treatment to remove the glycosylated
chains (Figure 4B). Whereas PrPSc associated to the DY strain
has a higher electrophoretical mobility, no significant differences
were observed among the other proteins. Another biochemical
property of misfolded PrP often used to differentiate prion strains
is its resistance to chemical denaturation (Safar et al., 1998).
Clear differences were observed in the guanidine concentrations
required to denature PrPSc associated to different strains
(Figure 4C). The concentration of the chaotropic agent needed
to denature 50% of PrPSc RML-Ha was 1.11 M, substantially
different from the 1.69, 1.56, and 1.72M required for the proteins
associated to HY, DY, and RML, respectively (Table S1).
Crossing the Hamster-Mouse Species Barrier
to Generate and Stabilize New Mouse Prions
To study thebarrier between these rodent species in the opposite
direction, we mixed 263K hamster prions with mouse healthy
brain homogenate. As before, when a standard PMCA assaywas done by dilution of 263K brain homogenate 1000-fold into
mouse healthy brain material, we did not see detectable genera-
tion of mouse PrPSc (data not shown). However, when a higher
quantity of hamster PrPSc was added, we were able to generate
newmousePrPSc (termed263K-Mo) that couldbepropagatedby
serial rounds of PMCA to reach a dilution of the hamster brain ho-
mogenate equivalent to 1017 (Figure 5A). Since there are not
available antibodies capable of recognizing mouse PrP but not
hamster PrP, we could not compare the electrophoretical pattern
of PrPSc generated in the first rounds of PMCA with the profile of
PrPSc typically observed inmouseandhamster strains.However,
the western blot pattern of 263K-Mo after 15 rounds of PMCA
(when no more molecules of 263K PrPSc are present) is similar
to the one observed for RML and other ovine-derived mouse
strains, despite a slightly faster migration (Figure S1A) that will
be investigated inmoredetail later. Toassesswhether newlygen-
erated PrPSc was indeed coming from conversion of mouse PrPC
induced by 263K hamster PrPSc and not just spontaneous ‘‘de
novo’’ formation of PrPSc in mice, we did an experiment to ana-
lyze the possibility of spontaneous generation of PrPSc and infec-
tivity under our experimental conditions.Samplesof healthybrain
homogenate from ten different mice were subjected to serial
rounds of PMCAamplification in the absence of PrPSc seed. After
up to 20 serial rounds of PMCA, we did not observe de novo for-
mation of PrPSc in any of the samples (Figure S1B).Cell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc. 761
Figure 4. Biochemical Characterization of
RML-Ha PrPSc
Samples from brains of animals inoculated with
RML-Ha PrPSc (first passage in vivo) were used
to study the PK resistance profile (A), the relative
mobility after deglycosylation and PK treatment
(B), and the susceptibility to guanidine denatur-
ation (C). For controls, we used samples from
RML or three distinct hamster strains (263K,
Hyper, and Drowsy). The results in (A) and (C)
correspond to the quantitative evaluation of west-
ern blots by densitometric analysis from three in-
dependent animals. The data represent the
average ± standard error. The data were analyzed
by ANOVA and the Dunnett multiple comparison
post-test. Each set of data was compared to the
results obtained with the RML-Ha strain, and
significant differences are highlighted with
asterisks (* = p < 0.05, ** = p < 0.01, and *** =
p < 0.001).To assess whether mouse PrPSc generated in vitro from ham-
ster 263K is infectious to wild-type mice and to determine
whether the infectious properties are being adapted upon serial
PMCA passages, we inoculated several rounds of in vitro-gener-
atedmaterial intomice (Figure 5A). Despite the fact that the same
amount of PrPSc was inoculated (as determined bywestern blot),
striking differences in the infectious properties were seen among
in vitro-generated prions in distinct rounds of PMCA (Figure 5B).
Only two of the six mice inoculated with material produced in the
first round of PMCA showed disease symptoms, which appear at
a very long time after inoculation (around 500 days) (Figures 5B
and 5C). A complete attack rate was observed when animals
were inoculated with material produced after three serial rounds
of PMCA. However, the incubation period was long (around 310
days on average), and there was a large dispersion among ani-
mals (Figures 5B and 5C). The incubation period became stable,
short (around 165 days), and there was little dispersion after the
six serial rounds of PMCA. These findings indicate that upon
successive rounds of PMCA, the newly generated prion, after
crossing the species barrier, is becoming adapted and stabilized
to the new host, a process very similar to what is seen after sev-
eral passages in vivo. The large dispersion of incubation times
observed in the third round of PMCA suggests that more than
one strain has been generated upon crossing of the species bar-
rier and that successive in vitro amplification leads to the selec-
tion and cloning of the most efficient of these strains. The incu-
bation time for 263K-Mo after 15 rounds of PMCA (equivalent
to a 1017 dilution of the 263K inoculum) was around 165 days,
similar to the one produced by scrapie-adapted mouse strains,
such as RML, but different from that of the bovine strain 301C
(Figure 5D). In vitro replication of the mouse strains RML and
301C at expense of mouse PrPC produced PrPSc with identical
properties as the brain-derived material, reflected as an indistin-
guishable incubation period (Figure 5D). As expected, mice inoc-
ulated with hamster 263K prions did not develop disease during
the time of the experiment (>500 days). No disease was also762 Cell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc.observed in animals inoculated with mouse brain homogenate
subjected to 20 rounds of PMCA in the absence of PrPSc, which
corresponds to the control experiment for the de novo genera-
tion of PrPSc (Figure 5D).
To analyze whether the newly generated 263K-Mo infectious
material corresponded to a new strain of mouse prions, we stud-
ied the histopathological and biochemical features of the brain
damage. Animals affected with the disease produced by inocu-
lation of 263K-Mo showed extensive vacuolation in the medulla
and hypocampus and moderate but clearly detectable damage
in the cerebellum (Figures 6A and 6D). The pattern of spongiform
degeneration does not correspond with any of the previously
known mouse strains studied and indeed is statistically signifi-
cantly different to the vacuolation profile produced by RML
and 301C prions (Figure 6D). Differences were also detected in
the extent of brain inflammation produced by 263K-Mo, since
the degree of astroglyosis was less prominent than the one ob-
served in animals inoculated with RML or 301C prions
(Figure 6B). The profile of PrPSc accumulation consisted mostly
of diffuse deposition and was not clearly different from the one
observed in the other strains (Figure 6C). Then we studied the
biochemical characteristics of PrPSc obtained from the brain of
animals infected with 263K-Mo. Electrophoretical migration
was assessed after PK digestion and endoglycosidase treat-
ment to remove glycosylation chains. The PK-resistant core of
PrPSc migrated slightly faster than RML but slightly slower than
301C, with an estimated molecular weight of 20 KDa (Figures
7A and 7B). These results indicate that the cleavage site after
PK digestion is different from all of the currently known mouse
strains. This is important because it is thought that differences
in the PK cleavage site reflect disparities in the folding or aggre-
gation of the protein (Chen et al., 2000; Collinge et al., 1996). To
further search for biochemical differences, we subjected the pro-
tein to proteolytic degradation by using various concentrations
of PK. 263K-Mo PrPSc was much more resistant to PK than to
RML (Figure 7C), with a PK50 (the PK concentration needed to
Figure 5. In Vitro Conversion of Mouse PrPC Induced by Hamster 263K PrPSc Generates Infectious Prions
(A) Schematic representation of the dilutions done and the PMCA rounds used for our in vivo infectivity experiments.
(B) Survival curve observed after inoculation of six wild-typemicewith thematerial generated after several rounds of PMCA. ‘‘R’’ indicates the number of rounds of
PMCA. As a control, the animals were inoculated with 263K hamster prions.
(C) Average and standard error of the incubation times and attack rates observed after inoculation of wild-type mice with the material produced after different
rounds of PMCA.
(D) Comparison of survival curves for the stabilized 263K-Mo infectious material (after 15 rounds of PMCA) with those obtained with RML and 301C, two mouse
strains of different origin. We also show the data obtained by inoculation of in vitro-generated prions through 20 serial rounds of PMCA by incubation of RML
(RML-PMCA) or 301C (301C-PMCA) PrPSc with healthy mouse brain homogenate. The figure also show the results obtained by inoculation of the material pro-
duced after 20 rounds of PMCA with unseeded normal mouse brain homogenate (PMCA-No PrPSc), which correspond to the control for de novo generation of
prions. For all of these experiments, the material was inoculated i.c. as described in the Experimental Procedures.degrade half of the protein) of 1450 mg/ml (Figure 7D), much
larger than the values obtained for RML (240 ug/ml) and 301C
(430 ug/ml) (Table S2). Interestingly, the high resistance of PrPSc
is typical of the hamster prions (Table S1), and indeed, 263K, the
parental strain of the newly generated mouse prions, has a PK50
of around 1700 mg/ml.
DISCUSSION
The phenomenon of the species barrier, by which the agent
coming from one species can infect only a limited number of
other species, is a typical feature of prion diseases. The molec-
ular basis of this process is not well-understood, but it is thought
to be controlled by the structure and folding of the prion protein
(Moore et al., 2005; Vanik et al., 2004). As with the related phe-
nomenon of prion strains, it is difficult to imagine how an infec-
tious agent lacking genetic material and composed by a single
protein can encode the structural diversity and specificity re-
quired to control strains variability and species selectivity (Soto
and Castilla, 2004).In addition to the intriguing molecular mechanism behind the
species barrier, understanding this phenomenon has profound
implications for public health. Indeed, one of the scariest medical
problems of the last decades has been the emergence of a new
and fatal human prion disease (variant CJD) originated by cross-
species transmission of BSE from cattle (Will et al., 1996). BSE
has not only been transmitted to humans. The extensive use of
cow-derived material for feeding other animals led to the gener-
ation of new diseases in exotic felines, nonhuman primates, and
domestic cats (Doherr, 2003). Worrisomely, the transmission of
BSE into these different species could create new prion strains
with unique biological and biochemical characteristics and
thus a potentially new hazard for human health. More frightening
is perhaps the possibility that BSE has been passed into sheep
and goats. Studies have already shown that this transmission
is possible and actually relatively easy (Foster et al., 1993). The
disease produced is clinically similar to scrapie, but since it
comes from BSE it has the potential to be infectious to humans.
Another concern is CWD, a disorder affecting farm and wild spe-
cies of cervids (Sigurdson and Aguzzi, 2006;Williams, 2005). TheCell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc. 763
origin of CWD and its potential to transmit to humans are cur-
rently unknown. This is worrisome, considering that CWD has
became endemic in some parts of the USA and that the number
of cases continues to increase (Williams, 2005). CWD transmis-
sibility studies have been performed in many species in order to
predict how this disease could be spread by the consumption of
CWD meat (Sigurdson and Aguzzi, 2006). Transmission of CWD
to humans cannot be ruled out at present, and a similar infective
episode to BSE involving CWD could result in catastrophic
consequences.
Theexciting scientificproblemcoupledwith the relevant public-
health issue prompted us to develop strategies to reproduce the
species-barrier phenomenon in the test tube. We reported previ-
ously the generation of infectious prions in vitro by cyclic replica-
tion of the protein misfolding process featuring the pathogenesis
of prion diseases (Castilla et al., 2005). These results were repro-
duced and extended by other groups to better dissect the ele-
ments required for prion replication (Deleault et al., 2007; Weber
Figure 6. Histopathological Features of the Disease
Induced by Inoculation of Mice with PMCA-Generated
263K-Mo PrPSc
Brains from sick mice in which disease was produced by inoc-
ulation with the newly generated 263K-Mo prions after 15
rounds of PMCA (first passage) or the known mouse strains
RML and 301C were analyzed by histological studies. As
a control, we used brain of a mouse inoculated with PBS
and sacrificed without disease at 350 days after inoculation.
(A) Spongiform degeneration was evaluated after hematoxilin-
eosin (HE) staining of three different brain areas (cerebellum,
medulla, and hippocampus) and was visualized at a 403mag-
nification.
(B) Reactive astroglyosis was evaluated in the inferior cullicu-
lus by staining with glial fibrillary acidic protein antibody.
(C) PrP accumulation in these animals was evaluated in the
occipital cortex and cerebellum by staining of the tissue with
the 6H4 antibody.
(D) The vacuolation profile in each brain area was estimated
with a semiquantitative scale, as described in theExperimental
Procedures. The brain areas used were the following: occipital
cortex, cerebellum (mostly white matter), medulla (spinal 5 nu-
cleus, interpolar part), inferior colliculum, and hippocampus
(CA1 and CA2 regions). We also included in the analysis brain
sections from animals inoculated with RML and 301C. The
values represent the average ± standard error of the extent
of vacuolation from the five animals analyzed in each set. Sta-
tistical analysis by two-way ANOVA with brain regions and
prion origin as the variables indicated that differences were
highly significant (p < 0.001). To assess the significance of
the differences between each known prion strain and 263K-
Mo, we used the Dunnett multiple comparison post-test, and
the p values for each combination are shown.
et al., 2007). The PMCA technology has been adap-
ted to replicateprions fromvariousspecies (Deleault
et al., 2005; Jones et al., 2007; Kurt et al., 2007;Mur-
ayama et al., 2007; Sarafoff et al., 2005; Soto et al.,
2005) and even to use bacterially produced re-
combinant PrP as substrate (Atarashi et al., 2007).
The conclusion drawn from these studies together
with the findings reported in this manuscript is that
propagation of the PrPSc misfolding results in formation of infec-
tious material, which maintains the strains and species-barrier
properties of the original prions. Qualitatively similar conclusions
have been obtained for yeast prions, which are a group of ‘‘infec-
tious proteins’’ that behave as a non-Mendelian genetic element
and transmit biological information in the absence of nucleic
acid (Wickner et al., 1995). Recent studies showed that bacterially
produced N-terminal fragments of the yeast prions Sup35p and
Ure2p when transformed into amyloid fibrils were able to propa-
gate the prion phenotype to yeast cells (Brachmann et al., 2005;
KingandDiaz-Avalos, 2004;Tanakaetal., 2004). Infectionof yeast
with different conformers led to generation of distinct prion strains
in vivo (Brachmann et al., 2005; Tanaka et al., 2004). Remarkably,
yeast prions also show the species-barrier phenomenon, and re-
cent data indicate that strain conformation is the critical determi-
nant of cross-species prion transmission (Tanaka et al., 2005).
In the current study, we demonstrate the generation of new in-
fectious prions across the species barrier. For this purpose, we764 Cell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc.
Figure 7. Biochemical Characteristics of 263K-Mo PrPSc
(A) Samples frombrainsofmice inoculatedwith 263K-Mo,RML, or 301Cwereused to study theelectrophoreticalmigration after deglycosylationandPK treatment.
(B) For assessment of the electrophoretical differences among distinct strains, the blot in (A) was scanned and analyzed by software included in the UVP image
analysis system to locate the exact position of the bands.
(C) The PK resistance profile of 263K-Mo PrPSc was studied and compared with RML.
(D) The results of the experiment shown in (B) were quantitated by densitometric analysis. The data in the figure represent the average ± standard error from
three independent animals. The differences were statistically significant as evaluated by one-way ANOVA (p < 0.01).mixed PrPSc from one species with PrPC from a different animal
species and subjected the mixture to serial rounds of PMCA to
generate, propagate, and stabilize new prion strains. Hamster
PrPSc generated from mouse RML prions was infectious to
wild-type hamsters. Detailed analysis of the disease characteris-
tics and comparison with the illness produced by several known
hamster prion strains indicate that the in vitro-generated infec-
tious material across the species barrier corresponds to a new
prion strain in hamsters (termed RML-Ha). The main differences
of the RML-Hawere on the incubation times after i.p. inoculation,
the extremely high resistance to PK degradation, and the pattern
of brain damage (Table S1). Similarly, PrPSc generated by con-
version of mouse PrPC with hamster PrPSc from the 263K strain
was shown to be infectious to wild-type mice, with an incubation
period comparable to that obtained after inoculation with some
of the mouse-adapted scrapie strains, such as RML. Again, the
disease produced by the new prions (termed 263K-Mo) was
clearly distinguishable from the one produced by some of the
currently known mouse prion strains. The major differences
were seen in the electrophoretical migration, extremely high re-
sistance to proteolytic degradation, and pattern of brain spongi-
form degeneration (Table S2). To rule out that newly generated
PrPSc in these experiments was coming from ‘‘de novo’’ sponta-
neous conversion of PrPC into PrPSc during PMCA, we used
samples of healthy brain homogenate from ten different miceand hamsters that were subjected to serial rounds of PMCA am-
plification in the absence of PrPSc seed. After up to 20 serial
rounds of PMCA, we did not observe de novo formation of PrPSc
in any of the samples. Thismaterial was inoculated into wild-type
animals, and no disease was observed more than 400 days after
inoculation. These results strongly indicate that the generation of
PrPSc reported in the present studywas due to interspecies prion
conversion. Nevertheless, we would like to highlight that recently
we have been able to generate in vitro PrPSc de novo without ad-
dition of PrPSc seed (data not shown). However, to reach this
aim, the PMCA conditions need to be modified. The modifica-
tions include changes on the PMCA parameters (length of incu-
bation and potency of sonication), preincubation, or pretreat-
ment of the normal brain homogenate to induce/stabilize PrP
misfolding prior to PMCA. These findings suggest that de novo
formation of PrPSc can be experimentally distinguished from
replication of preformed PrPSc, indicating that the biochemical,
conformational, or stability properties of the PrP structures in-
volved in both processes are probably different. Standard
PMCA conditions, as those used in the current study, do not re-
sult in spontaneous PrPSc formation.
Interestingly, in our serial PMCA amplifications of RML PrPSc
into hamster PrPC, we observed a progressive change on the
western blot profile of the newly generated RML-Ha PrPSc. In-
deed, in the first round of PMCA, the glycoform distributionCell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc. 765
pattern was reminiscent of RML and later switched to a profile
typical of the hamster strains, characterized by the predomina-
tion of the diglycosylated form (Figure 1D). Our interpretation of
this result was that consecutive rounds of PMCA may enable
the new prion strain to adapt and stabilize. To further study
this possibility in our experiments in which mouse prions were
generated from 263K hamster prions, we inoculated the material
generated after various rounds of PMCA. Strikingly, similar
amounts of PrPSc generated after one and three rounds of
PMCA produced disease with incomplete attack rates and/or
very long incubation periods (Figures 5B and 5C). Incubation
time stabilized after six rounds of serial PMCA, suggesting that
at this point the new strain is fully adapted. These findings sug-
gest that PMCA is not only able to reproduce the interspecies
transmission of prions but is also able to mimic the strain adap-
tation process observed in vivo. In vivo adaptation and stabiliza-
tion of prions generated after crossing the species barrier takes
at least four consecutive passages, which requires several years
of work (Race et al., 2001, 2002). Conversely, strain adaptation
by PMCA takes only 2 or 3 weeks. Importantly, the kinetics of ad-
aptation in vitro and in vivo, as well as the characteristics of the
stabilized material, are very similar. Indeed, it has been reported
that three serial passages of 263K in mice produce disease in all
animals, with an incubation time of around 300 days (Race et al.,
2002). This result is very similar to the data obtained with the ma-
terial generated in vitro after three successive rounds on PMCA
replication (Figures 5B and 5C). Moreover, less than three in vivo
passages produced an incomplete attack rate, and more than
three passages are needed to obtain a stable and low incubation
period (Race et al., 2002), which is in the same range of our 263K-
Mo infectious material. Finally, similar to our in vitro data, the
in vivo cross-species transmission between hamsters and
mice also led to the generation of unique prion strains (Race
et al., 2001, 2002). Although we are tempted to speculate that
each PMCA round has the same effect on strain adaptation as
did each in vivo passage, more experiments with other species
combinations are needed to reach this conclusion.
In summary, our results show that all elements controlling in-
terspecies transmission of prions are contained in a cell-free sys-
tem and that new prion strains can be generated, adapted, and
stabilized upon crossing the species barrier in vitro by PMCA.
These findings provide additional support for the prion hypothe-
sis, suggesting that species-barrier transmission and strain gen-
eration are determined by the propagation of PrP misfolding.
Furthermore, the data demonstrate that PMCA is a valuable
tool for the investigation of the strength of the barrier between
diverse species, its molecular determinants, and the expected
features of the new infectious material produced. Finally, our
findings suggest that the universe of possible prions is not re-
stricted to those currently known but that likely many unique in-
fectious foldings of the prion protein may be produced and that
one of the sources for this is cross-species transmission.
EXPERIMENTAL PROCEDURES
Preparation of Tissue Homogenates
Healthy and sick animals were perfused with phosphate-buffered saline (PBS)
plus 5 mM ethylenediaminetetraacetic acid (EDTA) before the tissue was har-766 Cell 134, 757–768, September 5, 2008 ª2008 Elsevier Inc.vested. Ten percent brain homogenates (w/v) were prepared in conversion
buffer (PBS containing 150 mM NaCl, 1.0% Triton X-100, and the complete
cocktail of protease inhibitors from Boehringer Mannheim, Mannheim, Ger-
many). The samples were clarified by a brief, low-speed centrifugation (1500
rpm for 30 s) with an Eppendorf centrifuge (Hamburg, Germany), model 5414.
Serial Replication of Prions In Vitro by PMCA
Aliquots of 10% brain homogenate from clinically sick mice infected with RML
or 301C and hamsters infected with 263K, HY, or DY prions were diluted into
10% hamster or mouse healthy brain homogenate. Samples were loaded onto
0.2 ml PCR tubes and positioned on an adaptor placed on the plate holder of
a microsonicator (Misonix Model 3000, Farmingdale, NY). Each PMCA cycle
consisted of 30 min incubation at 37C followed by a 20 s pulse of sonication
set at potency of 7. Samples were incubated without being shaken immersed
in the water of the sonicator bath. After a round of PMCA cycles, a 10 ml aliquot
of the amplified material was diluted into 90 ml of more normal brain homoge-
nate, and a new round of PMCA cycles was performed. This procedure was
repeated several times to reach the final dilutions indicated in the text. The de-
tailed protocol for PMCA, including reagents, solutions, and troubleshooting,
has been published elsewhere (Castilla et al., 2006; Saa et al., 2005).
Proteinase K Degradation Assay
The standard procedure for digestion of PrPSc consists of subjecting the sam-
ples to incubation in the presence of PK (50 mg/ml) for 60 min at 37C. The di-
gestion was stopped by addition of electrophoresis sample buffer, and the
protease-resistant PrP was revealed by western blotting. So that the profile
of PK sensitivity for in vitro- and in vivo-generated PrPSc could be studied,
the samples were incubated for 60 min at 37C with different concentrations
of PK ranging from 0 to 2500 mg/ml. The PK50 values represent the concentra-
tion of PK needed to digest half of the protein, and these values are estimated
on the basis of the densitometric analysis of three replicated western blots.
Guanidine Denaturation Assay
Samples were incubated with different concentrations of guanidine hydrochlo-
ride for 2 hr at room temperature with shaking. Thereafter, samples were
incubated in the presence of 10% sarkosyl for 30 min at 4C and centrifuged
at 100,000 3 g for 1 hr in a Biosafe Optima MAX ultracentrifuge (Beckman
Coulter, Fullerton, CA). The pellet of the centrifugation was resuspended in
conversion buffer and treated with PK as described above. Equivalent aliquots
of pellet were analyzed by western blot. The Gdn50 value corresponds to
the concentration of guanidine hydrochloride required to denaturate 50%
of the protein, and these values were estimated on the basis of the
densitometric analysis of three replicated western blots.
Protein Deglycosylation Assay
PrPSc samples were first digested with PK as describe above. After addition of
10% sarkosyl, samples were centrifuged at 100,0003 g for 1 hr at 4C, super-
natant was discarded, and the pellet resuspended in 100 ml of glycoprotein de-
naturing buffer (New England Biolabs, Beverly, MA) and incubated for 10 min
at 100C. Thereafter, 26 ml of 50mMsodium phosphate (pH 7.5) containing 1%
nonidet P-40 and 3 ml of peptide N-glycosidase F (New England Biolabs, Bev-
erly, MA) were added. Samples were incubated for 2 hr at 37C, and the reac-
tion was stopped by the addition of electrophoresis buffer and samples were
analyzed by western blot.
Western Blot
Proteins were fractionated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions, electroblotted into ni-
trocellulose membrane, and probedwith 6H4 (for mouse samples) and 3F4 (for
hamster samples) antibodies at a 1:5000 dilution. The immunoreactive bands
were visualized by enhanced chemoluminesence assay (Amersham, Piscat-
away, NJ) with an UVp image analysis system. So that the quantity of PrPSc
in the western blot would be assessed, densitometric analyses were done
by triplicate.
PrPSc Quantification
To inject the same quantity of PrPSc from each preparation, we compared the
samples by western blotting after PK digestion. To obtain a reliable and robust
quantification, we ran several different dilutions of the sample in the same gel,
to avoid artifacts due to saturation of the signal or to too weak of a signal.
Infectivity Studies
In vivo infectivity studies were done in C57Bl6 femalemice or Golden Syrian fe-
male hamsters, purchased fromCharles river. Animals were 4 to 6weeks old at
the time of inoculation. Anesthesized animals were injected stereotaxically into
the right hippocampuswith 2or 4ml of themouseor hamster infectiousmaterial,
respectively. For the i.p. infectivity studies, 100 ml of the sample were injected
into the peritoneal cavity. The quantity of infectious material injected corre-
sponds to the plateau portion of the incubation period; therefore, small differ-
ences in the amount of infectivity should not change incubation period unless
there are strain differences. The onset of clinical disease was measured by
scoring of the animals twice a week. For mice, the following scale was used:
1, normal animal; 2, roughcoat on limbs; 3, extensive roughcoat, hunckback,
and visible motor abnormalities; 4, urogenital lesions; and 5, terminal stage of
the disease in which the animal presented with cachexia and lies in the cage
with little movement. For hamsters, the following scoring scale was used: 1,
normal animal; 2, mild behavioral abnormalities including hyperactivity and hy-
persensitivity to noise; 3,moderate behavioral problems including tremor of the
head, ataxia, wobbling gait, head bobbing, irritability, and aggressiveness (or
lethargy in case of the DY strain); 4, severe behavioral abnormalities including
all of the above plus jerks of the head andbody and spontaneous backrolls; and
5, terminal stage of the disease inwhich the animal lies in the cage and is no lon-
ger able to stand up. Animals scoring level 4 during two consecutive weeks
were considered sick and were sacrificed to avoid excessive pain via exposi-
tion to carbonic dioxide. Brains were extracted, the right cerebral hemisphere
was frozen and stored at 70C for biochemical examination of PrPSc with
western blots, and the left hemisphere was used for histology analysis.
Histopathological Studies
Brain tissue was fixed in 10% formaldehyde solution, cut in sections, and em-
bedded in paraffin. Serial sections (6 mm thick) from each block were stained
with hematoxylin-eosin, or incubated with monoclonal antibodies recognizing
PrP or the glial fibrillary acidic protein, via our previously described protocols
(Castilla et al., 2005). Samples were visualized with a Zeiss microscope. The
vacuolation profile was estimated by consideration of both number and size
of spongiform degeneration in five different brain areas: occipital cortex, cer-
ebellum (mostly white matter), medulla (spinal 5 nucleus, interpolar part), infe-
rior colliculum, and hippocampus (CA1 and CA2 regions). Each analyzed brain
area was scored from 0 to 4 according to the extent of vacuolation in slides
stained with hematoxilin-eosin and visualized at a 403magnification. Samples
were analyzed blindly by two different persons, and the scores represent the
average of the two determinations.
Statistical Analysis
The differences in incubation periods, histopathological profile of brain dam-
age, and biochemical characteristics of PrPSc were analyzed by ANOVA, fol-
lowed by the Dunnett Multiple Comparison post-test to estimate the signifi-
cance of the differences between the newly generated strains and each of
the other hamster and mouse prion strains studied. For these studies, the
data were analyzed with the GraphPad Instat, version 3.05 software.
SUPPLEMENTAL DATA
Supplemental Data include one figure and two tables and can be found with
this article online at http://www.cell.com/cgi/content/full/134/5/757/DC1/.
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